SCHEMBL3472406

SCHEMBL3472406

N#CC(c1ccccc1C(F)(F)F)N1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ACHE P22303 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 2/20 0.40
AKR1C3 P42330 1/20 0.40
CNR2 P34972 1/20 0.39
KCNA5 P22460 1/20 0.39
DPP4 P27487 1/20 0.38
MC4R P32245 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OPRL1 P41146 1/20 0.38
PRKDC P78527 1/20 0.37
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779689 0.82 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL2781199 0.79 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL11460899 0.77 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL16796793 0.76 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL9413499 0.75 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL2781893 0.74 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL11159935 0.74 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1
SCHEMBL14593340 0.74 CACNA2D1 (0.43) MAPT
SCHEMBL3470982 0.73 DPP4 (0.67) AKR1C3CNR2KCNA5DPP4MC4R
SCHEMBL11158619 0.73 RPS6KB1 (0.54) ALDH1A1SMN1; SMN2ACHEL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105663-A1 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS BAYER HEALTHCARE AG (DE) 2010-04-29 US disclosed
US-20100105663-A1 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS BAYER HEALTHCARE AG (DE) 2010-04-29 US disclosed
US-20100105663-A1 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS BAYER HEALTHCARE AG (DE) 2010-04-29 US disclosed
WO-2008006479-A1 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS BAYER HEALTHCARE AG (DE) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105663-A1 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS F2, TFPI, PLAT ALDH1A1 2776/4885SMN1; SMN2 4341/4885ACHE 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.